Aintree University Hospital NHS
NHS Foundation Trust
Where quality matters

MERSEY HEAD & NECK ONCOLOGY RESEARCH GROUP

UNIVERSITY OF LIVERPOOL

HEAD & NECK ONCOLOGY CLINICAL TRIALS

Welcome to the first edition of the 'Head and Neck Oncology Clinical Trials' Newsletter.
The rationale for the newsletter is to keep all staff associated with the 'Merseyside Regional Head and Neck Cancer Centre' up to date with studies currently open and recruiting at Aintree as well as news on possible future studies, studies that have closed and any other relevant information relating to our activity.
The plan is for the newsletter to have a quarterly distribution frequency with scope for special

Research Studies currently open and recruiting at Aintree:

Randomised Controlled Trials:
HOPON – 53 patients recruited
SEND – 25 patients recruited
REALISTIC – 13 patients recruited
TRISMUS – 7 patients recruited
LIHNCS – 60 patients recruited

Cohort Studies:
Head & Neck 5000 – 362 patients recruited
Advanced Cancer Study – 6 patients recruited
Predictr – 40 patients currently on study
HPV Prevalence – 167 patients currently on study

For more information on the specific nature of each of these studies open the excel worksheet.

Trial info 1.2.xlsx

Focus on Tissue Banking

The Head & Neck Oncology Clinical Trials Team works very closely with the University of Liverpool Tissue Banks to collect samples from a range of head and neck conditions as well as suspected and confirmed head and neck cancers.
Collection involves: (after discussion with the Surgeon) obtaining samples from involved tissue and non involved adjacent tissue as well as blood plasma and white cells.
All patients having biopsies, lesion or tumour resections will be considered and hopefully recruited for tissue donation to the:
Liverpool University – Liverpool Tissue Bank
Liverpool University – Molecular Determinants of Head and Neck Cancer Study.
The team at Aintree has up to now collected –
196 samples for the Liverpool Tissue Bank and -
22 samples for the Molecular Determinants of Head and Neck Cancer Study.

If you require information about any of the ongoing Head & Neck Oncology studies or implementation of any new studies, please contact:
Shirley Pringle, Nicola Carmichael or Paul Banks Head & neck Oncology Research Practitioners or
Linda Kearns, Data Manager
TEL: 0151 529 5873

CANCER RESEARCH UK
EPRC
Liverpool Cancer Trials Unit

Aintree University Hospital NHS
NHS Foundation Trust
Where quality matters

UNIVERSITY OF LIVERPOOL

MERSEY HEAD & NECK ONCOLOGY RESEARCH GROUP

HEAD & NECK 5000 is halfway there!

'Congratulations! Well done to all of the Head & Neck 5000 study teams as we now have 2500 patients consented to the study. Please carry on with the good work so that we can reach our target of 5000 by the end of next year.
You are doing a fantastic job at Aintree, so far you are responsible for just over 14% of study recruitment. We are all really pleased with the work that you are doing!
Best wishes and a huge thank you from all of us here for all the work that you are putting in to the study'.

Katrina Hurley
Senior Research Nurse, Head & Neck 5000 Study



Coming Soon – Dahanca 21 – Hyperbaric Oxygen Treatment of Mandibular ORN

HBO stimulates monocyte and fibroblast proliferation as well as collagen synthesis in irradiated tissue. Also, angiogenesis is stimulated, resulting in an increased vascularity. Moreover, recent research shows that HBO induces bone marrow derived progenitor cells in previously irradiated humans and animals.
At this point, there is not sufficient scientific evidence for a clinical effect of HBO on ORN.
The objective of the study is to evaluate the effect of HBO on mandibular ORN as an adjunctive to surgical treatment in patients previously irradiated for head and neck cancer
Patients will be randomised equally between the following arms:
Group I: The participants of group I will receive 30 preoperative HBO treatment sessions and immediately thereafter surgical removal of the necrotic bone/conservative treatment. Then, 10 postoperative HBO sessions are given. The date of the intervention is registered as the first day of the follow-up period.
Group II: The participants of group II do not receive HBO treatment, but surgery/conservative treatment as described above. The date of the intervention is registered as the first day of the follow-up period.
Awaiting Trust approval.

Thyroid Cohort Study DeteQT closes to recruitment

Dear Professor Jones
I would like to extend my thanks for all the effort that you and your team have put into
recruiting to DeteQT and making it a success.
On behalf of all the team here I am grateful for your input.
I will be in touch in due course with a copy of the manuscript once it is written in draft form.
Yours sincerely
Professor Hisham Mehanna PhD, BMedSc (hons), MBChB (hons), FRCS, FRCS (ORL-HNS)

CANCER RESEARCH UK
EPRC
Liverpool Cancer Trials Unit